Neurocrine biosciences presents new data on ingrezza® (valbenazine) capsules at psych congress 2024: majority of long-term study participants achieved remission of tardive dyskinesia

San diego , nov. 4, 2024 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) presented data from the long-term kinect®-4 study demonstrating tardive dyskinesia remission in nearly 60% of participants at week 48 with once-daily ingrezza® (valbenazine) capsules treatment. this research, "remission of tardive dyskinesia in patients receiving long-term valbenazine treatment" (poster #98), was shared at the 2024 psych congress in boston.
NBIX Ratings Summary
NBIX Quant Ranking